TG Therapeutics, Inc. (TGTX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-192.3%

-$55.98

vs $60.64 price

Levered DCF

-$72.21

After debt service

Piotroski score

5 / 9

Average

Altman Z-score

5.82

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	9.62×	188.13×	191.27×	-8.1×	-7.22×	-21.5×	-5.66×	-1.78×
P/B	6.64×	19.67×	15.11×	27.34×	10.59×	11.55×	25.4×	12.87×
P/S	6.98×	13.29×	10.38×	575.19×	375.58×	39,471.44×	6,453.25×	2,035.62×
EV / EBITDA	33.37×	89.13×	93.58×	-7.43×	-6.7×	-20.13×	-5.43×	-1.54×
Gross margin	83.7%	88.3%	94.0%	90.5%	88.2%	100.0%	100.0%	42.1%
Operating margin	20.0%	12.7%	8.8%	-7839.0%	-5154.3%	-179996.1%	-111220.4%	-114736.8%
Net margin	72.6%	7.1%	5.4%	-8036.3%	-5204.1%	-183803.3%	-113730.9%	-114132.9%
Current ratio	4.1×	6.25×	5.92×	3.16×	5.06×	6.99×	1.77×	2.03×
Debt / equity	0.4×	1.14×	0.69×	1.42×	0.33×	0.08×	1.06×	0×
Interest coverage	4.61×	1.75×	1.64×	-21.42×	-61.15×	-43.23×	-31.98×	-100.58×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	69.0%	10.5%	7.9%	-382.0%	-146.8%	-53.8%	-447.7%	-721.8%
Return on invested capital	13.5%	7.8%	7.2%	-153.8%	-108.9%	-48.7%	-210.8%	-387.0%
Return on assets	42.1%	4.0%	3.8%	-115.6%	-91.7%	-44.7%	-106.0%	-207.5%
Free cash flow yield	-0.6%	-0.9%	-1.3%	-11.0%	-11.8%	-3.6%	-13.6%	-41.7%
Earnings yield	10.4%	0.5%	0.5%	-14.0%	-13.9%	-4.7%	-17.6%	-56.1%
Enterprise value	$4.5B	$4.4B	$2.4B	$1.6B	$2.3B	$5.5B	$909.1M	$267.5M
Net debt / EBITDA	1.35×	1.48×	0.68×	0.09×	0.64×	1.88×	0.43×	0.24×
Cash conversion cycle (days)	247	1,191	1,108	0	76	0	0	-110,458